Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan Partnership aims to include Aclarion’s surgical decision support technology within ATEC’s AlphaInformatiX platform to better inform spine surgery Aclarion’s Nociscan is the first augmented...

Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care....

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain George...

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually. The International Society for the Advancement...

Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium NociscanTM  is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a...